All In Biotech

Drug Trial Radar · NCT06548672

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

A Phase Ia/Ib, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

148

Planned (sponsor's estimate)

Start

Jun 24, 2024

Primary completion

Apr 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression or intolerance). This study will consist of two parts: Dose escalation (Part 1) and dose expansion (Part 2). Each part will include a screening period, a treatment period, and follow-up period.

Conditions

  • Advanced Cancer
  • Metastatic Solid Tumor

Interventions

  • BC3195Drug

    BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: First 21 days of treatment
  2. Determination of the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)Time frame: Day 1 of treatment through 30 days after the last dose
  3. Incidence and Severity of All Adverse Events (AEs)Time frame: Screening through 12 weeks after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Case Western Reserve University

    Cleveland, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.